Biohaven Q1 net loss $130.5M; pivotal epilepsy & obesity data due 2H 2026

Biohaven Ltd.

2026-Q1 EPS reported -$0.88

Net loss $130.5M ($0.88/sh) vs $221.7M ($2.17/sh) in Q1 2025; non-GAAP adjusted loss $102.2M ($0.69/sh).
Cash, equivalents & securities totaled $351.8M at March 31, 2026.
R&D spend fell to $103.8M from $187.6M, driven by program reprioritization and lower share-based compensation.
Pivotal epilepsy (opakalim) topline readout and Phase 2 obesity (taldefgrobep) data expected in 2H 2026.
Pivotal trials for BHV-1400 (IgAN) and BHV-1300 (Graves' disease) expected to initiate mid-2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Biohaven Ltd. reported financial results for first quarter ended March 31, 2026.

Period: first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 4, 2026, Biohaven Ltd. (the " Registrant ") issued a press release announcing its financial results for the first quarter ended March 31, 2026.

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Biohaven Ltd. filing history →

Source: SEC EDGAR

accession 0001935979-26-000044

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.